Results 41 to 50 of about 64,955 (112)

Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial

American Journal of Respiratory and Critical Care Medicine
Rationale A phase II trial reported clinical benefit over 28 weeks in patients with idiopathic pulmonary fibrosis (IPF) who received zinpentraxin alfa. Objectives To investigate the efficacy and safety of zinpentraxin alfa in patients with IPF in a phase
Luca Richeldi, C. Schiffman, Jürgen Behr, Yoshikazu Inoue, T. Corte, Vincent Cottin, R. G. Jenkins, S. Nathan, Ganesh Raghu, Simon L. F. Walsh, P. K. Jayia, N. Kamath, Fernando J Martinez   +12 more
semanticscholar   +1 more source

Prevalencia de anemia y su manejo clínico en la enfermedad renal crónica estadios 3-5 no en diálisis en cataluña: Estudio MICENAS I [PDF]

, 2014
Introducción: La anemia es una complicación frecuente de la enfermedad renal crónica (ERC). El objetivo de este estudio fue conocer la prevalencia de anemia en pacientes con ERC estadios 3-5 no en diálisis atendidos en consultas externas (CCEE) de ...
Agraz Pamplona, Irene, Arias-Rodríguez, Manuel A., Ballarín Castan, José Aurelio, Barbosa, Francesc, Bayés Genís, Beatriu, Bonal Bastons, Jordi, Cao, Higinio, Cases Amenós, Aleix, Castellote, Eugenia, Cañas, Laura, Coll Piera, Elisabeth, Collado, Sílvia, Craver, Lourdes, Felip, Àngela, Fort-Ros, Joan, Galcerán-Gui, Josep María, García, Rosario Pérez, Lauzurica, Ricardo, Martínez-Castelao, Alberto M., Martínez-Vea, Alberto, Perelló, Manel, Pou, Monica, Puig, C., Puig, Josep María, Ruiz, M. Pilar, Samon, Rosa, Universitat Autònoma de Barcelona, Vallés-Prats, Martín   +27 more
core   +1 more source

Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease

Frontiers in Genetics
Fabry disease, a rare X-linked genetic disorder, results from pathogenic variants in GLA, leading to deficient lysosomal α-galactosidase A enzyme activity and multi-organ manifestations. Since 2001, enzyme replacement therapy (ERT), using agalsidase alfa
Dominique P. Germain, Aleš Linhart
semanticscholar   +1 more source

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

New England Journal of Medicine, 2019
Background Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa ...
S. Connolly, M. Crowther, J. Eikelboom, M. Gibson, J. Curnutte, J. Lawrence, Patrick Yue, M. Bronson, Genmin Lu, P. Conley, P. Verhamme, Jeannot Schmidt, S. Middeldorp, A. Cohen, J. Beyer-Westendorf, P. Albaladéjo, J. López-Sendón, A. Demchuk, D. Pallin, M. Concha, S. Goodman, J. Leeds, Sonia Souza, D. Siegal, E. Zotova, Brandi Meeks, S. Ahmad, J. Nakamya, T. Milling   +28 more
semanticscholar   +1 more source

Anemia: definition, epidemiology, pathophysiology, classification, clinical picture, and treatment [PDF]

, 2019
Anemia é a redução da massa de hemoglobina e, portanto, da massa eritrocitária. Sua consequência é a hipóxia tecidual. A anemia é a manifestação de uma doença de base que muitas vezes está oculta. Ela afeta mais de um bilhão de pessoas em todo o mundo. A
De Santis, Gil Cunha
core   +2 more sources

Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry

Orphanet Journal of Rare Diseases
Background Hypophosphatasia (HPP) is a rare inherited disease caused by deficient activity of tissue-nonspecific alkaline phosphatase. Many adults with HPP have a high burden of disease, experiencing chronic pain, fatigue, limited mobility, and dental ...
P. Kishnani, G. Martos-Moreno, Agnès Linglart, A. Petryk, Andrew Messali, S. Fang, C. Rockman-Greenberg, Keiichi Ozono, W. Högler, L. Seefried, K. Dahir   +10 more
semanticscholar   +1 more source

Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.

Journal of the American Society of Nephrology, 2020
BACKGROUND Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. METHODS This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat's noninferiority to ...
T. Akizawa, M. Iwasaki, Y. Yamaguchi, Y. Majikawa, M. Reusch   +4 more
semanticscholar   +1 more source

Insuficiência cardíaca e anemia : atualização de conceitos e práticas : trabalho de revisão [PDF]

, 2016
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2016A insuficiência cardíaca (IC) é uma síndrome frequente, cuja prevalência aumenta com o avançar da idade, tendo elevada morbilidade e mortalidade.
Fernandes, Ana Raquel Menezes
core  

Eficacia de los activadores continuos de los receptores de eritropoyetina metoxi-polietilenglicol epoetina beta (MIRCERA) en comparación con Eritropoyetina recombinante humana (EporH) alfa en corrección inicial de la anemía secundaria a E. R.C en los pacienetes del programa de hemodiálisis del Hospital Militar Escuela Militar Dr. Alejandro Dávila Bolaños Abril a Octubre del 2013 [PDF]

, 2014
Se realizó un estudio experimental analítico controlado abierto en el programa de hemodiálisis del Hospital Militar Escuela Dr. ADB del universo de 114 pacientes en terapia dialítica al momento del estudio se seleccionó un total de 26 paciente atreves ...
Corea Urbina, karla Zinica
core  

Papel de los estimulantes de eritropoyesis en la anemia neonatal [PDF]

, 2021
Anemia is a pathology commonly found in the neonatal population, due to a series of physiological and non-physiological risk factors that contribute to the development of the disease.
Carvajal-Alzate, Manuela, Coronado-Magalhaes, Gabriela, Martínez-Sanchez, Lina María, Morales-Quintero, Natalia, Roldan-Tabares, Mabel Dahiana, Roldán-Isaza, Mariana   +5 more
core   +1 more source